Skip to main content

Table 3 Model variables: utilities

From: Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer

  Sensitivity analysis
Base value Minimum Maximum Distribution
Combination therapy     
 Stable disease 0.72 0.54 0.9 Binomial
 Treatment complication 0.72 0.54 0.9 Binomial
 Progression 0.59 0.4425 0.7375 Binomial
 Progression with complication 0.59 0.4425 0.7375 Binomial
 Death 0 0 0 Binomial
Monotherapy     
 Stable disease 0.73 0.5475 0.9125 Binomial
 Treatment complication 0.73 0.5475 0.9125 Binomial
 Progression 0.59 0.4425 0.7375 Binomial
 Progression with complication 0.59 0.4425 0.7375 Binomial
 Death 0 0 0 Binomial